AbCellera Biologics Inc. (ABCL)
Analysts are bullish on AbCellera Biologics Inc. (ABCL), predicting a 474% upside potential. Recent social posts highlight the company's AI-driven platform and potential for long-term value.
About AbCellera Biologics Inc.
AbCellera Biologics Inc. is a biotechnology firm focused on antibody research and development using a proprietary platform for drug discovery.
AbCellera Biologics Inc. uses the ticker $ABCL for trading. Listed in the Stocks category within the Healthcare sectors.
Insights
- AbCellera Biologics Inc. (ABCL) Galaxy Score™ near a 52-week high at [--].
- AbCellera Biologics Inc. (ABCL) Galaxy Score™ is up 79.49% from the previous [--] months.
- AbCellera Biologics Inc. (ABCL) sentiment is up 12.16% from the previous week.
- AbCellera Biologics Inc. (ABCL) posts created is up 81.54% from the previous week.
Price: $3.10
Price 24-Hour Time-Series Raw Data
The price action for $ABCL appears to be driven by a mix of positive sentiment and technical analysis, with some anticipating upward trends, though concerns about revenue volatility and market valuation of partnerships may be tempering extreme optimism. Recent social posts indicate accumulation and positive technical outlooks, suggesting potential for upward movement.
24-Hour: 1.64% 7-Day: -6.63% 30-Day: -24.76%
1-Year High: $6.20 on 2025-10-08
1-Year Low: $2.40 on 2025-06-05
AltRank: [---]
AltRank 24-Hour Time-Series Raw Data
AbCellera Biologics Inc. (ABCL) is currently AltRank #473 based on combined combined social and market metrics
Daily Average: [---]
[--] Week: [---] [----]
1-Year High: [-----] on 2026-02-03
1-Year Low: [---] on 2026-01-24
Galaxy Score: [-----]
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [--]
[--] Week: [--] +10
[--] Month: [--] +30
[--] Months: [--] +30
[--] Year: [--] +26
1-Year High: [--] on 2026-01-23
1-Year Low: [--] on 2026-01-19
Engagements: [------] (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: [------]
Daily Average: [------]
[--] Week: [-------] -9.20%
[--] Month: [---------] +13%
[--] Months: [----------] +16%
[--] Year: [----------] +560%
1-Year High: [-------] on 2026-01-23
1-Year Low: [-----] on 2025-03-31
Engagements by network (24h): News: [---] Reddit: [---] TikTok: [--] X: [------] YouTube: [--]
Mentions: [---] (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: [---]
Daily Average: [---]
[--] Week: [---] +0.97%
1-Year High: [-----] on 2025-07-22
1-Year Low: [--] on 2025-04-27
Mentions by network (24h): News: [--] Reddit: [--] TikTok: [--] X: [---] YouTube: [--]
Creators: [---] (24h)
Creators 24-Hour Time-Series Raw Data
[---] unique social accounts have posts mentioning AbCellera Biologics Inc. (ABCL) in the last [--] hours which is down 19% from [---] in the previous [--] hours
Daily Average: [---]
[--] Week: [---] -0.67%
1-Year High: [---] on 2025-07-22
1-Year Low: [--] on 2025-04-27
The most influential creators that mention AbCellera Biologics Inc. in the last [--] hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @jinseongeo83473 | [--] | [-----] | [--] | [-----] |
| @ugurrnek | [--] | [---] | [--] | [---] |
| @StockChaser_ | [--] | [------] | [--] | [---] |
| @iamrocketmen | [--] | [------] | [--] | [---] |
| @BCValueInvestor | [--] | [---] | [--] | [---] |
| @InvestmentGuru_ | [--] | [------] | [--] | [---] |
| @snmart | [--] | [--] | [--] | [---] |
| @10xValueMind | [--] | [-----] | [--] | [---] |
| @Stock_Analysis5 | [--] | [--] | [--] | [---] |
| @SilviaO55229084 | [--] | [--] | [--] | [---] |
Sentiment: 80%
Sentiment 24-Hour Time-Series Raw Data
Current Value: 80%
Daily Average: 84%
[--] Week: 83% +9%
[--] Month: 76% -1%
[--] Months: 76% -7%
[--] Year: 76% -15%
1-Year High: 100% on 2025-03-19
1-Year Low: 21% on 2025-03-05
Most Supportive Themes:
- Strong Long-Term Potential and Value: (40%) The community sees significant long-term value and potential in $ABCL, with many investors believing it could be a major winner.
- AI-Driven Platform and Innovation: (30%) The AI-driven platform for drug discovery and antibody engineering is highlighted as a key differentiator and valuable asset.
- Positive Technical Analysis and Price Targets: (20%) Several posts indicate positive technical analysis, with specific price targets and expectations of upward trends and new all-time highs.
Most Critical Themes:
- Revenue Volatility and Partnership Dependence: (70%) The company's revenue is noted as volatile and heavily reliant on partnerships, posing a risk to consistent financial performance.
- Market Valuation of Partnerships: (30%) There's a sentiment that the market is currently undervaluing the company's partnerships, which are seen as a significant future asset.
Social Dominance: 0.02%
Social Dominance 24-Hour Time-Series Raw Data
Current Value: 0.02%
Daily Average: 0.027%
[--] Week: 11.60% +11.50%
[--] Month: 0.037% +0.013%
[--] Months: 0.037% -0.031%
[--] Year: 0.037% +0.024%
1-Year High: 0.126% on 2025-07-22
1-Year Low: 0.0037% on 2025-05-01
Market Dominance: 0.00109%
Market Dominance 24-Hour Time-Series Raw Data
Current Value: 0.00109%
Daily Average: 0%
1-Year High: 0.046% on 2026-01-22
1-Year Low: 0.00109% on 2026-02-16
Market Cap: $957,872,154
Market Cap 24-Hour Time-Series Raw Data
Current Value: $957,872,154
Daily Average: $1,104,717,376
[--] Week: $957,872,154 +0.95%
[--] Month: $927,938,649 -25%
1-Year High: $1,388,914,623 on 2026-01-22
1-Year Low: $832,151,433 on 2026-02-05
Top AbCellera Biologics Inc. News
Top news links shared on social in the last [--] hours
Showing a maximum of [--] news posts without a LunarCrush subscription.
"AbCellera Biologics Inc. (ABCL): Analysts See 474% Upside Potential We recently published an article titled [--] Best Multibagger Stocks to Invest in Now. AbCellera Biologics Inc. (NASDAQ:ABCL) was one of the stocks that was covered in that article. Wall Street analysts believe ABCL has a 474% upside potential over the next [--] months. AbCellera Biologics Inc. (NASDAQ:ABCL) is an AI-powered biotechnology company specializing in antibody"
News Link @YahooFinance 2025-06-02T20:28Z 2M followers, [----] engagements
Top AbCellera Biologics Inc. Social Posts
Top posts by engagements in the last [--] hours
Showing a maximum of [--] top social posts without a LunarCrush subscription.
"They specifically highlight AbCellera $ABCL as attractive post-selloff. Why Biologic data is high-dimensional closed-source and built over years not easily replicated by generic AI models"
X Link @ugurrnek 2026-02-16T10:24Z [---] followers, [---] engagements
"Strong update $ABCL Im aligned on most of this. Its been a little over a year since I wrote my first article on AbCellera. Heres an update of what Im looking at for the rest of [--] and beyond: A development over the past year has been the companys shift towards prioritizing in-house molecules. They successfully moved https://t.co/zFVPZDd6Cc Its been a little over a year since I wrote my first article on AbCellera. Heres an update of what Im looking at for the rest of [--] and beyond: A development over the past year has been the companys shift towards prioritizing in-house molecules. They"
X Link @ugurrnek 2026-02-16T08:13Z [---] followers, [---] engagements
"$ABCL Its a proprietary data flywheel. - Microfluidics ➡ millions of immune responses - Difficult targets (GPCRs) ➡ high technical moat - Clinical validation (635) ➡ platform repricing If they crack GPCR antibodies they validate a dataset no AI model can replicate. Its been a little over a year since I wrote my first article on AbCellera. Heres an update of what Im looking at for the rest of [--] and beyond: A development over the past year has been the companys shift towards prioritizing in-house molecules. They successfully moved https://t.co/zFVPZDd6Cc Its been a little over a year since I"
X Link @snmart 2026-02-16T08:12Z [--] followers, [---] engagements
"Hey Jack great write-up on $ABCL as always. Thank you so much. Quick question have you thought about the GLP-1/obesity optionality for AbCellera's GPCR platform GLP-1R is a Class B GPCR. Amgen is already validating antibody-based GPCR targeting in this space with MariTide (anti-GIPR antibody + GLP-1 peptides) showing 20% weight loss at [--] weeks with monthly dosing. If [---] validates the GPCR platform the optionality goes way beyond hot flashes. Nobody knows if AbCellera will ever touch this space but just curious if it's something you've thought about."
X Link @iamrocketmen 2026-02-16T00:56Z 16.5K followers, [----] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing